Superior vena cava syndrome (SVCS)

Superior vena cava syndrome (SVCS) is a clinical syndrome resulting from partial or complete obstruction of blood flow through the superior vena cava (SVC). Approximately 90% of cases are caused by malignancy, making SVCS an important oncological emergency. Obstruction leads to impaired venous drainage from the head, neck, upper extremities, and upper thorax, resulting in venous congestion and edema. In patients with non-small cell lung cancer, SVCS is associated with advanced disease and poor prognosis. Prompt recognition, diagnosis of the underlying cause, and timely treatment are essential to relieve symptoms and prevent life-threatening complications.

Epidemiology

Malignancy accounts for approximately 90% of cases of superior vena cava syndrome.

The common malignant causes include:

• Lung cancer (approximately 65%)

• Lymphomas (approximately 15%)

• Other malignancies (approximately 10%)

Less commonly, SVCS results from benign causes such as thrombosis associated with central venous catheters or cardiac devices.

Risk factors

Risk factors include:

• Lung cancer

• Lymphoma

• Mediastinal tumors

• Metastatic malignancy involving the mediastinum

• Central venous catheters

• Implantable cardiac devices

• Superior vena cava thrombosis

• Hypercoagulable states

Pathophysiology

Superior vena cava syndrome develops when blood flow through the superior vena cava is obstructed by external compression, intraluminal obstruction, or thrombosis.

The major mechanisms include:

Extrinsic compression

• Lung cancer (approximately 65%)

• Lymphoma (approximately 15%)

• Other cancers (approximately 10%)

Intrinsic obstruction

• Superior vena cava thrombosis

• Tumor invasion into the vessel lumen

Progressive obstruction causes increased venous pressure proximal to the obstruction, resulting in edema of the face, neck, upper limbs, and upper chest, venous distension, reduced cerebral venous drainage, and occasionally airway compromise.

Clinical presentation

Symptoms usually develop gradually but may occur rapidly in acute thrombosis. Severity depends on the degree and speed of venous obstruction and the development of collateral venous circulation.

Symptoms

• Dyspnoea

• Headache

• Facial swelling

• Neck swelling

• Upper limb swelling

• Change in skin colour involving the face, neck, or upper limbs

• Cough

• Hoarseness

• Chest discomfort

• Dysphagia

• Dizziness

• Syncope (severe cases)

Clinical signs

• Facial oedema

• Neck oedema

• Upper limb oedema

• Venous distension of the neck

• Dilated veins over the upper chest and arms

• Facial plethora or cyanosis

• Raised jugular venous pressure

• Pemberton's sign, characterized by facial flushing, distended neck and superficial head veins, inspiratory stridor, and elevation of the jugular venous pressure when both arms are raised above the head.

• Respiratory distress in severe cases

Differential diagnosis

• Congestive heart failure

• Angioedema

• Superior mediastinal mass without SVC obstruction

• Pulmonary embolism

• Constrictive pericarditis

• Pericardial tamponade

• Allergic reactions causing facial swelling

• Deep vein thrombosis involving upper extremities

Diagnostic criteria

The diagnosis of SVCS is based on characteristic clinical features supported by imaging demonstrating obstruction of the superior vena cava and identification of the underlying cause.

Diagnosis is established by:

• Clinical features consistent with impaired venous drainage from the upper body.

• Imaging confirming superior vena cava obstruction.

• Histological confirmation of malignancy where appropriate before initiating definitive treatment whenever clinically feasible.

Investigations

• Chest X-ray (CXR)

• CT scan of the chest, abdomen, and pelvis

• PET/CT scan where indicated

• Tissue diagnosis to determine the underlying malignancy and guide treatment

• Bronchoscopy

• Needle aspiration of peripheral lymph nodes or mediastinoscopy

• Sputum cytology

• Thoracentesis where pleural effusion is present

Management

Management consists of supportive measures to relieve symptoms and definitive treatment directed at the underlying cause.

Initial management includes:

• Assess airway, breathing, and circulation.

• Evaluate for airway compromise or cerebral edema requiring urgent intervention.

• Elevate the head of the bed.

• Obtain tissue diagnosis whenever possible before initiating definitive therapy, unless immediate treatment is required because of life-threatening airway or neurological compromise.

Non-pharmacological treatment

Supportive measures

• Elevate the head of the bed to reduce hydrostatic pressure and improve facial and upper limb edema.

• Avoid placement of intravenous cannulas or infusion lines in the upper limbs whenever possible to prevent worsening venous congestion.

• Remove central venous devices if they are responsible for thrombosis or obstruction.

Definitive therapy

Treatment depends on the underlying cause.

• Radiotherapy for malignant tumors causing superior vena cava compression.

• Chemotherapy for chemosensitive malignancies such as lymphoma, germ cell tumors, and small cell lung cancer.

• Superior vena cava stent placement for thrombosis or persistent obstruction despite cancer treatment.

• Surgical intervention may be considered in selected patients with benign causes or when other treatments are unsuccessful.

Pharmacological treatment

Supportive therapy

To reduce inflammation and edema:

• Dexamethasone – 4 mg – route according to clinical indication – every 6 hours – duration according to clinical response.

To reduce fluid overload where appropriate:

• Furosemide – administer according to clinical indication and patient response.

Management according to underlying cause

Lung cancer

• Tissue diagnosis followed by radiotherapy and/or systemic therapy according to tumor type and stage.

Lymphoma

• Obtain tissue diagnosis before corticosteroid administration whenever feasible.

• Chemotherapy is the primary treatment.

Small cell lung cancer

• Chemotherapy is the preferred initial treatment.

Germ cell tumors

• Systemic chemotherapy is recommended.

Superior vena cava thrombosis

• Consider superior vena cava stent placement.

• Remove causative central venous devices where appropriate.

• Manage thrombosis according to institutional protocols.

Persistent or recurrent obstruction

• Consider superior vena cava stenting if symptoms persist despite oncological treatment.

Referral

Urgently refer patients with suspected or confirmed SVCS to an oncology or thoracic specialist.

Immediate referral is indicated for patients with:

• Airway compromise

• Severe respiratory distress

• Cerebral edema

• Altered level of consciousness

• Rapidly progressive facial or upper airway swelling

• Hemodynamic instability

• Suspected malignant superior vena cava obstruction requiring urgent tissue diagnosis and treatment

Complications

• Airway obstruction

• Cerebral edema

• Increased intracranial pressure

• Respiratory failure

• Superior vena cava thrombosis

• Venous thrombosis of the upper extremities

• Recurrent obstruction

• Disease progression related to underlying malignancy

Prognosis

The prognosis depends primarily on the underlying cause. Patients with malignant SVCS generally have advanced disease, and survival is determined by the type and stage of the malignancy. Symptoms often improve rapidly following appropriate radiotherapy, chemotherapy, or endovascular stenting, particularly in chemosensitive tumors.

Prevention

Prevention focuses on early diagnosis and treatment of mediastinal malignancies and minimizing the risk of catheter-related thrombosis. Appropriate placement and timely removal of central venous devices, together with prompt investigation of persistent facial swelling or unexplained upper body venous congestion, may reduce complications.